6833 — Sinco Pharmaceuticals Holdings Share Price
- HK$496.03m
- HK$295.62m
- CNY2.54bn
- 36
- 90
- 33
- 54
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 0.7 | ||
Price to Tang. Book | 0.83 | ||
Price to Free Cashflow | 1.53 | ||
Price to Sales | 0.17 | ||
EV to EBITDA | 2.06 |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | 17.36% | ||
Return on Equity | 6.88% | ||
Operating Margin | 4.5% |
Financial Summary
Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | CNYm | 1,176.41 | 2,049.8 | 2,024.06 | 2,271.51 | 2,540.06 | n/a | n/a | 21.66% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | +401.29 | +11.34 | -56.03 | -39.08 | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Sinco Pharmaceuticals Holdings Limited operates as one provider of marketing, promotion and channel management (MPCM) services in the People's Republic of China (PRC) pharmaceutical industry. It provides its integrated MPCM services to small- and medium-sized overseas pharmaceutical manufacturers that do not possess independent marketing and promotion capabilities in China. Its major product is human albumin solution, a human albumin product manufactured by Octapharma, which is used to remedy hypovolemia and hypovolemic shock, abnormally high intracranial pressure, edema and ascites, and to prevent and cure hypoalbuminemia and neonatal hyper-bilirubinemia. In addition, its products include axetine, medocef, esafosfina, tad and taurolite.
Directors
- Xiangbin Huang CHM (49)
- Min Jin CCE (43)
- Yifan Li CFO (36)
- Zhizheng Li SVP (42)
- Guowei Liu VOP (39)
- Fei Peng CTR (42)
- Yue Wu DSL (36)
- Ling Bai OTH (36)
- Haibin Hu OTH (43)
- Xianghong Li OTH (31)
- Kin Wai Li SEC
- Yunlu Peng SEC (29)
- Zhizhong Bai NID (63)
- Ying Kit Lau NID (44)
- Wenfang Liu NID (82)
- Qing Wang NID (51)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- March 16th, 2015
- Public Since
- March 10th, 2016
- No. of Employees
- 266
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Stock Exchange of Hong Kong Limited
- Shares in Issue
- 2,032,890,585
![Blurred out image of a map](https://www.stockopedia.com/assets/conversion/images/maps_placeholder.jpg)
- Address
- E5-1805, Global Center, No. 1700, CHENGDU
- Web
- https://www.sinco-pharm.com/zh-cn/
- Phone
- +86 2862912988
- Auditors
- Ernst & Young
Upcoming Events for 6833
Similar to 6833
3D Medicines
Stock Exchange of Hong Kong Limited
3SBio
Stock Exchange of Hong Kong Limited
AIM Vaccine Co
Stock Exchange of Hong Kong Limited
Ascletis Pharma
Stock Exchange of Hong Kong Limited
Asymchem Laboratories Tianjin Co
Stock Exchange of Hong Kong Limited
FAQ
As of Today at 23:19 UTC, shares in Sinco Pharmaceuticals Holdings are trading at HK$0.23. This share price information is delayed by 15 minutes.
Shares in Sinco Pharmaceuticals Holdings last closed at HK$0.23 and the price had moved by -26.88% over the past 365 days. In terms of relative price strength the Sinco Pharmaceuticals Holdings share price has underperformed the FTSE Developed Asia Pacific Index by -30.03% over the past year.
There is no consensus recommendation for this security.
The Sinco Pharmaceuticals Holdings dividend yield is 1.63% based on the trailing twelve month period.
Last year, Sinco Pharmaceuticals Holdings paid a total dividend of CNY0.00, and it currently has a trailing dividend yield of 1.63%. We do not have any data on when Sinco Pharmaceuticals Holdings is to next pay dividends.
We do not have data on when Sinco Pharmaceuticals Holdings is to next pay dividends. The historic dividend yield on Sinco Pharmaceuticals Holdings shares is currently 1.63%.
To buy shares in Sinco Pharmaceuticals Holdings you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of HK$0.23, shares in Sinco Pharmaceuticals Holdings had a market capitalisation of HK$475.70m.
Here are the trading details for Sinco Pharmaceuticals Holdings:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 6833
Based on an overall assessment of its quality, value and momentum Sinco Pharmaceuticals Holdings is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Sinco Pharmaceuticals Holdings. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -6.32%.
As of the last closing price of HK$0.23, shares in Sinco Pharmaceuticals Holdings were trading -7.08% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Sinco Pharmaceuticals Holdings PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at HK$0.23.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Sinco Pharmaceuticals Holdings' management team is headed by:
- Xiangbin Huang - CHM
- Min Jin - CCE
- Yifan Li - CFO
- Zhizheng Li - SVP
- Guowei Liu - VOP
- Fei Peng - CTR
- Yue Wu - DSL
- Ling Bai - OTH
- Haibin Hu - OTH
- Xianghong Li - OTH
- Kin Wai Li - SEC
- Yunlu Peng - SEC
- Zhizhong Bai - NID
- Ying Kit Lau - NID
- Wenfang Liu - NID
- Qing Wang - NID